HTFL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HTFL is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has supportive analyst sentiment, no negative news flow, and strong gross margin expansion, while the current pre-market price sits near technical support. The lack of strong insider or hedge-fund activity is neutral rather than bearish. Given the investor is impatient and does not want to wait for a perfect entry, this is an acceptable entry now rather than a stock to keep waiting on.
Current trend is mixed-to-bearish in the very short term but not broken. MACD histogram is -0.15 and negatively expanding, which shows near-term weakness. RSI_6 at 44.78 is neutral, so the stock is not oversold but also not stretched. Moving averages are converging, suggesting a potential turning point rather than a strong trend. Price at 29.76 is slightly above S1 support at 29.364 and close to S2 at 28.293, while still below the pivot at 31.098. That means the stock is trading near support in pre-market, which is a reasonable long-term entry area.
["Canaccord raised its price target to $43 and kept a Buy rating.", "JPMorgan maintained Overweight and said Q4 was good, with Plaque ahead of expectations.", "Company reported a solid Q4 beat.", "Initial 2026 guidance is viewed by analysts as highly conservative.", "Ongoing Plaque Analysis launch is expected to drive momentum.", "Gross margin expanded strongly to 79.51% in Q4 2025."]
["No news in the recent week, so there is no immediate event-driven upside catalyst.", "MACD is still negative and weakening, showing near-term price pressure.", "EPS declined sharply year over year to -0.29.", "Revenue was flat year over year in the latest quarter.", "No recent insider buying or hedge fund accumulation trends were detected.", "No recent congress trading data is available."]
In Q4 2025, Heartflow posted revenue of 49.13 million, flat year over year, which suggests top-line growth is not yet accelerating. Net income remained negative at -24.395 million, and EPS fell to -0.29, showing the company is still loss-making. The positive standout is gross margin, which improved to 79.51%, up 5.91% year over year, indicating better operating efficiency and product economics. Overall, the latest quarter was stronger on profitability quality than on revenue growth.
Analyst sentiment is positive overall. Canaccord raised its target to $43 from $40 and maintained Buy, citing a solid Q4 beat and conservative 2026 guidance. JPMorgan lowered its target to $35 from $40 but kept Overweight, also describing Q4 as good and Plaque ahead of expectations. The Wall Street view is constructive: pros see improving execution and upside from Plaque Analysis, while the main con is that targets are somewhat mixed and near-term growth expectations may already be partly reflected.
